15:40:57 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-08 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-16 Ordinarie utdelning SENZA 0.00 SEK
2024-05-15 Kvartalsrapport 2024-Q1
2024-05-15 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning SENZA 0.00 SEK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning SENZA 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-11 Bokslutskommuniké 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning SENZA 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning SENZA 0.00 SEK
2020-05-08 Årsstämma 2020
2020-02-13 Bokslutskommuniké 2019
2019-12-18 Extra Bolagsstämma 2019
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning SENZA 0.00 SEK
2019-05-15 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning SENZA 0.00 SEK
2018-05-08 Årsstämma 2018
2018-02-14 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Forskning och utveckling sker från huvudkontoret i Lund.
2023-09-28 08:30:00

SenzaGen continues its collaboration with the American Research Institute for Fragrance Materials (RIFM), in the area of in vitro photosensitization testing and fragrance safety. The new grant provided by RIFM marks another milestone in the partnership and will add SEK 1.6 million to SenzaGen’s sales. The testing will be performed at SenzaGen’s GLP-certified laboratory in Lund in 2023.

RIFM is a well-respected international scientific institute that, through an independent expert panel and a comprehensive library of chemicals, ensures the safe use of fragrance ingredients in consumer products. The collaboration between SenzaGen and RIFM commenced in 2021 and has gradually expanded, incorporating more ingredients with the aim of promoting animal-free testing and fragrance safety. In this project, SenzaGen will utilize its proprietary, unique method, GARD®skin Dose-Response, to assess fragrance ingredients from RIFM's reference library. The method has been adapted to identify the levels at which substances can induce skin allergies when exposed to sunlight (photosensitization).

"Our collaboration with RIFM continues to evolve into the field of photosensitization. Through this collaboration, we look forward to advancing non-animal scientific innovation and enhancing consumer safety. RIFM's scientific evaluations are a highly important reference for the industry and contribute to building up the knowledge base of our effective and accurate GARD® technology”, says Peter Nählstedt, President and CEO of SenzaGen.

"We are excited to continue our work with SenzaGen on the GARD®skin Dose Response assay for photosensitization. We have expanded our pool of reference chemicals to gain a deeper understanding of how the assay might help us identify potential photoallergens and even to distinguish photoirritants from photoallergens", says Gretchen Ritacco, Principal Scientist, Phototoxicology at RIFM.

The GARD®skin Dose-Response test method provides quantitative information and replaces animal testing when assessing the concentration at which skin-sensitizing substances can be used without causing skin allergies. In the RIFM project, the test materials are exposed to sunlight in one step to identify their photosensitization, providing companies in industries including cosmetics, pharmaceuticals and chemicals a crucial basis for prioritization and decision-making in research and development. The test is an expanded application domain of GARD®skin, and it is the first genomics-based test of its kind on the market.

For more information, please contact:
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobil: +46 700 23 44 31

Gretchen Ritacco, Principal Scientist, Phototoxicology, RIFM
Email: gritacco@rifm.org Mobil: +1-862-401-2978

About RIFM
Established in 1966, the Research Institute for Fragrance Materials (RIFM) generates, analyzes, evaluates, and distributes data to provide a scientific basis for the safe use of fragrances. RIFM has compiled the most comprehensive, worldwide source of toxicology data, literature, and general information on fragrance and flavor raw materials. RIFM’s Fragrance Ingredient Safety Assessment program draws from its comprehensive database of over 70,000 references and more than 135,000 human health and environmental studies.

RIFM assesses the safety of fragrance ingredients by the most current, internationally accepted guidelines—and has done so since its founding. The Expert Panel for Fragrance Safety, an independent, international team of researchers and academics with no ties to the fragrance industry, reviews all of RIFM’s work before RIFM submits it for peer-reviewed publication in a reputable scientific journal. RIFM makes all of its published, peer-reviewed work—current and historical—available for free at fragrancematerialsafetyresource.elsevier.com.